Butaclamol
In this article we are going to talk about Butaclamol, a topic that has been the subject of debate and discussion over the years. Butaclamol is a topic of great relevance in today's society, since it affects different areas of daily life, such as health, politics, culture and the economy. Throughout history, Butaclamol has played a fundamental role in forming identities and building communities. In this sense, it is important to analyze the impact that Butaclamol has had in different contexts and how it has evolved over time. Through this article, we aim to address different perspectives and aspects related to Butaclamol, in order to offer a comprehensive and enriching vision on this topic.
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H31NO |
| Molar mass | 361.529 g·mol−1 |
| 3D model (JSmol) | |
| |
Butaclamol (AY-23,028) is a type of antipsychotic which was never marketed.[1] Sold as the hydrochloride salt for use in research, the compound acts as a dopamine receptor antagonist.[2]
Chemistry
pKa = 7.15 (uncorrected for ionic strength)[3]
References
- ^ Buckingham J (1985). Dictionary of organic compounds - Google Books. CRC Press. ISBN 978-0-412-54090-5.
- ^ Hall DA, Strange PG (June 1997). "Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors". British Journal of Pharmacology. 121 (4): 731–6. doi:10.1038/sj.bjp.0701196. PMC 1564749. PMID 9208141.
- ^ Chrzanowski FA, McGrogan BA, Maryanoff BE (March 1985). "The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors". Journal of Medicinal Chemistry. 28 (3): 399–400. doi:10.1021/jm00381a022. PMID 2579238.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |